封面
市場調查報告書
商品編碼
1075560

奈米醫藥的全球市場 (2021年~2028年):各用途 (心臟血管、抗發炎藥、抗感染藥、神經、腫瘤、其他) 分析、規模、佔有率、成長、趨勢、預測

Nanomedicine Market (Application: Cardiovascular, Anti-inflammatories, Anti-infectives, Neurology, Oncology, and Others [Dental, Orthopedic, Urology, and Ophthalmic]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

出版日期: | 出版商: Transparency Market Research | 英文 81 Pages | 商品交期: 2-10個工作天內

價格

本報告提供全球奈米醫藥的市場調查,市場概要,市場成長的各種影響因素分析,技術趨勢,法律制度,市場規模的變化、預測,各種區分、各地區/主要國家的明細,競爭環境,主要企業簡介等彙整資訊。

目錄

第1章 序文

第2章 假設、調查手法

第3章 摘要整理:全球奈米醫藥市場

第4章 市場概要

  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 全球市場的分析、預測

第5章 重要洞察

  • 技術的進步
  • 主要的收購與合併
  • 法規情境:世界、各地區
  • COVID-19影響

第6章 全球奈米醫藥市場分析、預測:各用途

  • 簡介、定義
  • 主要調查結果、展開
  • 市場預測
    • 心臟血管
    • 抗發炎藥
    • 抗感染藥
    • 神經
    • 腫瘤
    • 其他
  • 市場魅力

第7章 全球奈米醫藥市場分析、預測:各地區

  • 主要調查結果
  • 市場預測
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東、非洲
  • 市場魅力

第8章 北美的奈米醫藥市場分析、預測

第9章 歐洲的奈米醫藥市場分析、預測

第10章 亞太地區的奈米醫藥市場分析、預測

第11章 南美的奈米醫藥市場分析、預測

第12章 中東及非洲的奈米醫藥市場分析、預測

第13章 競爭情形

  • 主要企業:競爭矩陣(各企業等級、規模)
  • 市場佔有率分析,各企業
  • 企業簡介
    • Abbott Laboratories
    • CombiMatrix Corporation
    • Celgene Corporation
    • GE Healthcare
    • Johnson &Johnson
    • Mallinckrodt plc
    • Merck &Company Inc.
    • Nanosphere, Inc.
    • Pfizer Inc.
    • Sigma-Tau Pharmaceuticals Inc.
    • Teva Pharmaceutical Industries Ltd
    • UCB SA
Product Code: TMRGL1753

Nanomedicine Market - Scope of Report

TMR's report on the global nanomedicine market studies past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2028. The report provides revenue of the global nanomedicine market for the period 2017-2028, considering 2020 as the base year and 2028 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global nanomedicine market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global nanomedicine market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global nanomedicine market.

The report includes an elaborate executive summary along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global nanomedicine market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global nanomedicine market.

The report delves into the competitive landscape of the global nanomedicine market. Key players operating in the global nanomedicine market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global nanomedicine market that have been profiled in this report.

Key Questions Answered in Nanomedicine Market Report

What is the scope of growth of product companies in the global nanomedicine market?

What will be the Y-o-Y growth of the global nanomedicine market between 2017 and 2028?

What is the influence of changing trends in technologies on the global nanomedicine market?

Will North America be the most profitable market for nanomedicine providers?

Which factors are anticipated to hamper the growth of the global nanomedicine market during the forecast period?

Which are the leading companies in the global nanomedicine market?

Research Methodology

TMR has utilized a unique research methodology to conduct comprehensive research on the growth of the global nanomedicine market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global nanomedicine market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR's study on the nanomedicine market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the nanomedicine market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global nanomedicine market with accuracy. The study also uses the top-down approach to assess the revenue for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR's estimates on future prospects of the global nanomedicine market more reliably and accurately.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Nanomedicine Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Nanomedicine Market Analysis and Forecast, 2017-2028

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Key Mergers & Acquisitions
  • 5.3. Regulatory Scenario by Region/globally
  • 5.4. COVID-19 Pandemics Impact on Industry

6. Global Nanomedicine Market Analysis and Forecast, by Application

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Application, 2017-2028
    • 6.3.1. Cardiovascular
    • 6.3.2. Anti-inflammatories
    • 6.3.3. Anti-invectives
    • 6.3.4. Neurology
    • 6.3.5. Oncology
    • 6.3.6. Others
  • 6.4. Market Attractiveness Analysis, by Application

7. Global Nanomedicine Market Analysis and Forecast, by Region

  • 7.1. Key Findings
  • 7.2. Market Value Forecast, by Region
    • 7.2.1. North America
    • 7.2.2. Europe
    • 7.2.3. Asia Pacific
    • 7.2.4. Latin America
    • 7.2.5. Middle East & Africa
  • 7.3. Market Attractiveness Analysis, by Region

8. North America Nanomedicine Market Analysis and Forecast

  • 8.1. Introduction
    • 8.1.1. Key Findings
  • 8.2. Market Value Forecast, by Application, 2017-2028
    • 8.2.1. Cardiovascular
    • 8.2.2. Anti-inflammatories
    • 8.2.3. Anti-infective
    • 8.2.4. Neurology
    • 8.2.5. Oncology
    • 8.2.6. Others
  • 8.3. Market Value Forecast, by Country, 2017-2028
    • 8.3.1. U.S.
    • 8.3.2. Canada
  • 8.4. Market Attractiveness Analysis
    • 8.4.1. By Application
    • 8.4.2. By Country

9. Europe Nanomedicine Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Application, 2017-2028
    • 9.2.1. Cardiovascular
    • 9.2.2. Anti-inflammatories
    • 9.2.3. Cardiovascular
    • 9.2.4. Neurology
    • 9.2.5. Oncology
    • 9.2.6. Others
  • 9.3. Market Value Forecast, by Country/Sub-region, 2017-2028
    • 9.3.1. Germany
    • 9.3.2. U.K.
    • 9.3.3. France
    • 9.3.4. Italy
    • 9.3.5. Spain
    • 9.3.6. Rest of Europe
  • 9.4. Market Attractiveness Analysis
    • 9.4.1. By Application
    • 9.4.2. By Country/Sub-region

10. Asia Pacific Nanomedicine Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Application, 2017-2028
    • 10.2.1. Cardiovascular
    • 10.2.2. Anti-inflammatories
    • 10.2.3. Anti-infective
    • 10.2.4. Neurology
    • 10.2.5. Oncology
    • 10.2.6. Others
  • 10.3. Market Value Forecast, by Country/Sub-region, 2017-2028
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Australia & New Zealand
    • 10.3.5. Rest of Asia Pacific
  • 10.4. Market Attractiveness Analysis
    • 10.4.1. By Application
    • 10.4.2. By Country/Sub-region

11. Latin America Nanomedicine Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Application, 2017-2028
    • 11.2.1. Cardiovascular
    • 11.2.2. Anti-inflammatories
    • 11.2.3. Anti-infectives
    • 11.2.4. Neurology
    • 11.2.5. Oncology
    • 11.2.6. Others
  • 11.3. Market Value Forecast, by Country/Sub-region, 2017-2028
    • 11.3.1. Brazil
    • 11.3.2. Mexico
    • 11.3.3. Rest of Latin America
  • 11.4. Market Attractiveness Analysis
    • 11.4.1. By Application
    • 11.4.2. By Country/Sub-region

12. Middle East & Africa Nanomedicine Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Application, 2017-2028
    • 12.2.1. Cardiovascular
    • 12.2.2. Anti-inflammatories
    • 12.2.3. Anti-infectives
    • 12.2.4. Neurology
    • 12.2.5. Oncology
    • 12.2.6. Others
  • 12.3. Market Value Forecast, by Country/Sub-region, 2017-2028
    • 12.3.1. GCC Countries
    • 12.3.2. South Africa
    • 12.3.3. Rest of Middle East & Africa
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Application
    • 12.4.2. By Country/Sub-region

13. Competition Landscape

  • 13.1. Market Player - Competition Matrix (by tier and size of companies)
  • 13.2. Market Share Analysis, by Company, 2020
  • 13.3. Company Profiles
    • 13.3.1. Abbott Laboratories
      • 13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.1.2. Financial Analysis
      • 13.3.1.3. Growth Strategies
      • 13.3.1.4. SWOT Analysis
    • 13.3.2. CombiMatrix Corporation
      • 13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.2.2. Financial Analysis
      • 13.3.2.3. Growth Strategies
      • 13.3.2.4. SWOT Analysis
    • 13.3.3. Celgene Corporation
      • 13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.3.2. Financial Analysis
      • 13.3.3.3. Growth Strategies
      • 13.3.3.4. SWOT Analysis
    • 13.3.4. GE Healthcare
      • 13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.4.2. Financial Analysis
      • 13.3.4.3. Growth Strategies
      • 13.3.4.4. SWOT Analysis
    • 13.3.5. Johnson & Johnson
      • 13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.5.2. Financial Analysis
      • 13.3.5.3. Growth Strategies
      • 13.3.5.4. SWOT Analysis
    • 13.3.6. Mallinckrodt plc
      • 13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.6.2. Financial Analysis
      • 13.3.6.3. Growth Strategies
      • 13.3.6.4. SWOT Analysis
    • 13.3.7. Merck & Company Inc.
      • 13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.7.2. Financial Analysis
      • 13.3.7.3. Growth Strategies
      • 13.3.7.4. SWOT Analysis
    • 13.3.8. Nanosphere, Inc.
      • 13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.8.2. Financial Analysis
      • 13.3.8.3. Growth Strategies
      • 13.3.8.4. SWOT Analysis
    • 13.3.9. Pfizer Inc.
      • 13.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.9.2. Financial Analysis
      • 13.3.9.3. Growth Strategies
      • 13.3.9.4. SWOT Analysis
    • 13.3.10. Sigma-Tau Pharmaceuticals Inc.
      • 13.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.10.2. Financial Analysis
      • 13.3.10.3. Growth Strategies
      • 13.3.10.4. SWOT Analysis
    • 13.3.11. Teva Pharmaceutical Industries Ltd
      • 13.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.11.2. Financial Analysis
      • 13.3.11.3. Growth Strategies
      • 13.3.11.4. SWOT Analysis
    • 13.3.12. UCB S.A.
      • 13.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.12.2. Financial Analysis
      • 13.3.12.3. Growth Strategies
      • 13.3.12.4. SWOT Analysis

List of Tables

  • Table 01: Global Nanomedicine Market Value (US$ Mn) Forecast, by Application, 2017-2028
  • Table 02: Global Nanomedicine Market Value (US$ Mn) Forecast, by Region, 2017-2028
  • Table 03: North America Nanomedicine Market Value (US$ Mn) Forecast, by Country, 2017-2028
  • Table 04: North America Nanomedicine Market Value (US$ Mn) Forecast, by Application, 2017-2028
  • Table 05: Europe Nanomedicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2028
  • Table 06: Europe Nanomedicine Market Value (US$ Mn) Forecast, by Application, 2017-2028
  • Table 07: Asia Pacific Nanomedicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2028
  • Table 08: Asia Pacific Nanomedicine Market Value (US$ Mn) Forecast, by Application, 2017-2028
  • Table 09: Latin America Nanomedicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2028
  • Table 10: Latin America Nanomedicine Market Value (US$ Mn) Forecast, by Application, 2017-2028
  • Table 11: Middle East & Africa Nanomedicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2028
  • Table 12: Middle East & Africa Nanomedicine Market Value (US$ Mn) Forecast, by Application, 2017-2028

List of Figures

  • Figure 01: Global Nanomedicine Market Value Share Analysis, by Application, 2021 and 2028
  • Figure 02: Global Nanomedicine Market Attractiveness Analysis, by Application, 2021-2028
  • Figure 03: North America Nanomedicine Market Value (US$ Mn) Forecast, 2017-2028
  • Figure 04: North America Nanomedicine Market Value Share Analysis, by Country, 2021 and 2028
  • Figure 05: North America Nanomedicine Market Attractiveness Analysis, by Country, 2021-2028
  • Figure 06: North America Nanomedicine Market Value Share Analysis, by Application, 2021 and 2028
  • Figure 07: North America Nanomedicine Market Attractiveness Analysis, by Application, 2021-2028
  • Figure 08: Europe Nanomedicine Market Value (US$ Mn) Forecast, 2017-2028
  • Figure 09: Europe Nanomedicine Market Value Share Analysis, by Country/Sub-region, 2021 and 2028
  • Figure 10: Europe Nanomedicine Market Attractiveness Analysis, by Country/Sub-region, 2021-2028
  • Figure 11: Europe Nanomedicine Market Value Share Analysis, by Application, 2021 and 2028
  • Figure 12: Europe Nanomedicine Market Attractiveness Analysis, by Application, 2021-2028
  • Figure 13: Asia Pacific Nanomedicine Market Value (US$ Mn) Forecast, 2017-2028
  • Figure 14: Asia Pacific Nanomedicine Market Value Share Analysis, by Country/Sub-region, 2021 and 2028
  • Figure 15: Asia Pacific Nanomedicine Market Attractiveness Analysis, by Country/Sub-region, 2021-2028
  • Figure 16: Asia Pacific Nanomedicine Market Value Share Analysis, by Application, 2021 and 2028
  • Figure 17: Asia Pacific Nanomedicine Market Attractiveness Analysis, by Application, 2021-2028
  • Figure 18: Latin America Nanomedicine Market Value Share Analysis, by Country/Sub-region, 2021 and 2028
  • Figure 19: Latin America Nanomedicine Market Attractiveness Analysis, by Country/Sub-region, 2021-2028
  • Figure 20: Latin America Nanomedicine Market Attractiveness Analysis, by Application, 2021-2028
  • Figure 21: Middle East & Africa Nanomedicine Market Value Share Analysis, by Country/Sub-region, 2021 and 2028
  • Figure 22: Middle East & Africa Nanomedicine Market Attractiveness Analysis, by Country/Sub-region, 2021-2028
  • Figure 23: Middle East & Africa Nanomedicine Market Attractiveness Analysis, by Application, 2021-2028